Drugs / Baiya SARS-CoV-2 Vax 2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05197712 | Mar 2022 → May 2023 | — | Baiya Phytopharm Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05873374 | Dec 2023 → Mar 2024 | COVID-19 | Baiya Phytopharm Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-08-25 | Baiya Phytopharm Co., Ltd. | Results BaiyaPhytopharm Announces Preliminary Results of the Phase 1 Clinical Trial of its COVID-19 Vaccine Baiya SARS-CoV-2 Vax 2 baiyaphytopharm.com ↗
Preliminary results of the first clinical trial on humans show that the vaccine is safe and that clinical trials should continue. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-08-25 | Baiya Phytopharm Co., Ltd. | BaiyaPhytopharm Announces Preliminary Results of the Phase 1 Clinical Trial of its COVID-19 Vaccine Baiya SARS-CoV-2 Vax 2 baiyaphytopharm.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Baiya SARS-CoV-2 Vax 2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05197712 ↗ |
| Known as | Baiya SARS-CoV-2 Vax 2 vaccine | “The investigational product Baiya SARS-CoV-2 Vax 2 vaccine is a second-generation of protein subunit vaccine from plant to prevent COVID-19 disease.” NCT05873374 ↗ |
| Modality | Vaccine | “The investigational product Baiya SARS-CoV-2 Vax 2 vaccine is a second-generation of protein subunit vaccine from plant.” NCT05197712 ↗ |
| Route | Intramuscular | “Intramuscular injection in the deltoid region” NCT05197712 ↗ |